Anti-FVSera. (B10.A × A.BY)FI or (B10.
A × A/WySn)F1 mice which had recovered from FV-induced splenomegaly 30-60 days after FV-B inoculation (15-150 focus-forming units [FFU] ) or 14-21 days after FV-N inoculation (1,500 FFU) were injected two to five times with 20-25 × 108 leukemic spleen cells obtained from syngeneic mice 8-9 days after intravenous inoculation with 1,500 FFU of FV-B. Mice were bled from the tail 7-14 days after the last injection to obtain anti-FV sera or were used as immune recipients in cell transfer experiments.
Anti-H-2 Sera. (C57BL/10 × BALB.B)F1 anti-(B10.D2 × BALB/c)F1 (anti-H-2 ~) and (B 10.D2 × BALB/e)FI anti-B 10.A(2R) (anti-H-2K k) sera were prepared as previously described (8) . In addition, NIH contract serum D-13 (C57BL/10 × LP.R III) anti-B10.A(SR) (anti-H-2D d) was used.
Cell Culture. AA41 (H-2 a) and Y57 (H-2 b) FV-induced leukemia cell lines were grown in tissue culture as described (9) . Primary cultures of leukemic spleen cells were incubated in RPMI-1640 medium with 10% fetal calf serum and 10 -5 M 2-mercaptoethanol at 0.1-7 × l0 s viable cells per ml.
Antibody Plus Complement (C')-Mediated Cytotoxicity.
A two stage cytotoxicity assay in microtiter trays was carried out using mouse leukemia-cell absorbed rabbit C' and SlCr-labeled target cells as previously described (5) . Target cells were normal or leukemic spleen cells, or AA41 or Y57 cell lines.
Quantitative Absorption. Anti-H-2 or anti-FV serum was diluted to the end of the plateau of the titration curve in the direct cytotoxicity assay. The serum was then absorbed with serial twofold dilutions of nucleated leukemic or normal spleen cells. 1-80 × 106 cells were placed in separate centrifuge tubes and spun for 10 rain at 2,000 rpm. The supernate was removed, and the cell pellet was subjected to a second (short) spin and residual supernate again removed. Then 85 #1 of diluted serum was added to each tube, and thecell pellet was suspended. The serum plus cells were incubated for 1 h at 4°C, and shaken once during this time. The cells were spun for 10 min at 2,000 rpm in the cold and 25-#1 triplicate samples of supernate from each tube were dispensed to microtiter trays for assay of cytotoxicity.
Membrane Immunofluorescence. Spleen cells were harvested and erythrocytes were lysed with Tris-buffered NH4CI for 10 rain at room temperature (10) . The cells were washed twice with phosphate-buffered balanced salt solution plus 2% fetal calf serum and 0.01 M NaNa. 4 × 106 cells were dispensed into 10 × 75-mm tubes and spun at 1,000 rpm for 5 min. Indirect membrane immunofluorescence was assayed as previously described (8), using anti-FV sera and fluorescein-conjugated rabbit anti-mouse immunoglobulin. For the direct membrane immunofluorescence assay, fluorescein-conjugated goat anti-Moloney leukemia virus (anti-MLV) (obtained from the NCI Viral Ontology Program; Huntington Research Center, lot 5010101) was absorbed twice for 40 min at room temperature with 100 mg acetone precipitated mouse liver and spleen tissue powder per milliliter serum and spun at 30,000 rpm for 10 rain. 5 #1 of absorbed serum was added to the cells to be tested and the cells were resuspended and incubated for 20 rain at 4°C, then washed twice and examined with a fluorescence microscope. Cells which had visible halos or patches of membrane fluorescence were scored as positive.
Intracellular
Immunofluorescence. 50-100 #1 of washed nucleated spleen cell suspension (2-10 x 10 s cells/ml) was placed on marked areas of microscope slides coated with 5% bovine serum albumin. The slides were placed in a humidity chamber, and the cells were allowed to settle onto the slide for 30 rain. Then the slides were placed in acetone at 4°C for 30 min or at -20°C for a minimum of 12 h. After removal from the acetone, slides were immediately washed in phosphate-buffered saline (PBS) at room temperature (10 rain three times with constant shaking), drained, and a 1/40 dilution of absorbed fluorescein-conjugated goat anti-MLV (see above) was added. The slides were then incubated for 1 h at 37°C in a humidity chamber washed three times in PBS at room temperature, dried, mounted in buffered glycerol mounting medium, and examined with a fluorescence microscope.
Irradiation. Mice were given 900 rads whole-body X-irradiation with a Maximar type III 250 KV deep therapy X-ray unit. The machine delivered 19.1 fads/rain at 24 inches from the target. (5) . Therefore, we wanted to determine whether leukemia cells from these mice could be lysed in vitro by anti-FV serum plus rabbit C'. High specific lysis (20-45%) was seen with leukemic spleen cells from 27 of 28 mice (96%) 8-9 days after FV-B inoculation (1,500 FFU) (Fig. 1) . In contrast, leukemic spleen cells of only 5 of 31 mice 30-90 days after FV-B inoculation had greater than 20% specific lysis. These results suggested that in later stages of the disease (>30 days after FV inoculation) the leukemic spleen cells of these Fa mice had reduced amounts of FV-induced cell surface antigens. Fluorescent Antibody Studies. To confirm and extend the cytotoxic antibody data with an antibody binding assay, virus-induced cell surface antigens on 8-9 day and >30 day leukemic spleen cells from F1 mice were also studied by membrane immunofluorescence. Cells were examined using both an indirect (mouse anti-FV serum Table I late F1 leukemic spleen cells transferred into unimmunized lethally irradiated recipients showed an increased percent (51-66%) of cells positive for FVspecific membrane immunofluorescence. These values were similar to those seen previously in early (8-9 day) spleen cell populations (Fig. 5) . Late F1 cells transferred to immune lethally irradiated recipients failed to show this increase. Recovered leukemic cells from both immune and nonimmune recipients were found to have high levels of cytoplasmic virus-specific fluorescence (63-92%) when acetone-fixed cells were examined. This indicated that virus-infected leukemia cells were not eliminated after transfer to either type of recipient. Early (8-9 day) leukemic spleen cells (66-76% positive membrane fluorescence) were similarly transferred to nonimmune and immune lethally irradiated recipients. 6-7 days after transfer into immune lethally irradiated recipients, 9-28% of recovered spleen cells were positive for membrane fluorescence (Table II) . The percent of cells positive for FV-induced cell membrane antigens remained high when the early spleen cells were transferred to unimmunized lethally irradiated recipients. In both types of recipient, cytoplasmic virus-specific fluorescence was seen in 53-62% of the spleen cells recovered 6-7 days after transfer.
Results

Lysis of FV-Induced Leukemia Cells with
Quantitation of FV-Induced
In Vitro Studies. Experiments were carried out to attempt to increase the expression of FV antigen on late shown). By indirect immunofluorescence and by cytotoxicity, the antibodies appeared to bind to the cell surface and remained there for the duration of the incubation (up to 48 h). No evidence for antigenic modulation was seen. Thus, we were unable to induce increased expression of FV-induced antigens on the leukemic spleen cells nor were we able to cause an antibody-mediated decrease or modulation of FV-induced cell membrane antigens in vitro. The mechanism of the reappearance of FV antigen on the late leukemic spleen cells injected into irradiated recipients is not completely clear. Antigen may be re-expressed on the original low antigen donor cell population and their progeny, or residual antigen positive leukemic cells may grow out after transfer to irradiated recipients. However, preliminary data indicate that pretreatment of the late leukemic spleen cell population with anti-FV antisera plus C' to kill residual antigen positive cells prior to injection into irradiated nonimmune recipients does not alter antigen re-expression (data not shown). This finding appears to exclude the possibility of the outgrowth of residual high antigen cells after adoptive transfer. Furthermore, since the same percent of cells was positive for virus-specific cytoplasmic fluorescence in the donor and the recipient spleens, it seems most likely that antigen was re-expressed on virus-infected cells after transfer to unimmunized recipients.
Since we had demonstrated the reversibility of the FV membrane antigen loss in vivo in a nonimmune environment, we attempted to induce a similar antigen increase in vitro. We were unable to observe an increase in FV-induced cell surface antigens on late F1 leukemic spleen cells when these cells were placed in tissue culture in the absence of anti-FV antibody. Conversely, since it was likely that cytotoxic antibody was involved in the induction of FV surface antigen loss observed in vivo, we attempted to induce a decrease in FV-induced cell surface antigen on early leukemic spleen cells by placing these cells in cultures with high concentrations of cytotoxic anti-FV serum. We were unable to decrease FV surface antigen on early cells with this technique, and were even unable to decrease antigen by using an anti-FV/antiimmunoglobulin sandwich technique (data not shown). Old et al. (12) were able to cause a selective loss of TL (thymus-leukemia) antigens on ascites leukemia cells cultured in vitro in the presence of anti-TL antisera, and in vivo in immunized recipients (13) . TL antigenic modulation was quite rapid and was shown to be an active metabolic process. The reappearance of TL antigen when the cells were cultured in the absence of anti-TL antibody was less rapid, and may have required several cell divisions (12). Genovesi et al. (14) observed modulation of FV antigen from the cell surface of a FV tumor line when incubated in vitro in the presence of anti-FV antibody. Antigenic modulation was seen to a greater extent when the cells were in logarithmic growth as compared to cells in a resting state. Failure of FV leukemic spleen cells to divide in vitro may explain why we were unable to induce in vitro modulation of FV antigens on early leukemic spleen cells or to observe FV antigen reappearance on late cells cultured in vitro. On the other hand, it is also possible that the FV antigen loss observed in vivo with leukemic spleen cells is substantially different from the antigenic modulation described with the TL system and with a FV tumor cell line in vitro.
Late F1 leukemic spleen cells retained intracellular or cytoplasmic FV-induced antigens while their surface antigens were lost. Ioachim et al. (15) , found a similar disjunction between membrane and cytoplasmic Gross murine leukemia virus (MuLV) antigen expression when G-MuLV lymphoma cells were injected into partially tolerized rats. Thus in both FV and G-MuLV systems, leukemia cells sometimes exhibit surface antigenic adaptations to immune pressures without altering intracellular antigen expression. This may be a means by which tumor cells escape immune destruction (16) . It is clear that the presence of cytotoxic anti-leukemia cell antibodies is not by itself sufficient to cause a recovery from leukemia (5). This may be because the leukemic cells become insensitive to antibody-mediated lysis as a result of a loss of FV-induced cell surface antigens. Similar findings have been reported for measles-virus infected cells which can also grow normally in the presence of cytotoxic anti-measles antibody (11) . In vivo studies of suppression of tumor-specific cell surface antigen expression (17, 18) have involved transfer of tumor cells to immune recipients in order to induce antigen loss. Ioachim et al. (15, 19) reported that transfer of Gross MuLV lymphoma cells to immune recipients induced a decreased tumor antigen expression, and this antigen loss was associated with increased tumorigenicity on subsequent transfer. In the present study, adoptive transfer of tumor cells was not required to induce antigen loss, and the observed decreased antigen expression may represent a tumor cell adaptation to host immune pressures generated during the course of FV leukemia.
Summary
Friend virus (FV)-induced leukemic spleen cells from (B10.A X A)F1 mice were found to lose sensitivity to antibody-mediated lysis during progression of erythroleukemia. This was correlated with a 78% loss of FV-induced cell surface antigens as determined by quantitative absorption of cytotoxic antibodies and with a decreased percentage of leukemic spleen cells showing membrane immunofluorescence with anti-FV antibody. Antigen loss was observed only with virus-induced antigens, and was limited to antigens expressed on the cell surface. FV-induced antigens were regained when low-antigen leukemia cells from late stages of the leukemia were transferred to lethally irradiated nonimmune recipients, but not when these cells were transferred to hyperimmune lethally irradiated recipients. Conversely, when highantigen leukemic spleen cells from early stages of the erythroleukemia were transferred to hyperimmune irradiated recipients, antigen loss was induced. The immune response to virus-induced antigens appeared to be involved in causing the antigenic changes observed on leukemia cells in this system.
